aktien-community.com

[Sheep]

[jheimi]

.

[blabla]

[Perestroika]

Also die Kursentwicklung ist schon sackstark!!!

Derzeit hilft nur Hoffnung auf bessere Zeiten...

Waiting for 2018!

greetz
Perestroika

[jheimi]

Im Moment ist COPN in einem unschönen Abwärtstrend. Die nächste Unterstützung sehe ich gemäss Chart leider erst bei ca. 125.-

[Perestroika]

auf dem Weg dort hin...

[jheimi]

Order bei 125.- ist drin. Leider wird bis im Mai nicht viel neues (Kurstreibendes) kommen.

[lost60]

VOLITION - COSMO
Serological biomarkers in triage of FIT-positive subjects?
Nielsen HJ1, Christensen IJ1, Andersen B2, Rasmussen M3, Friis-Hansen LJ4, Bygott T5, MiCallef J5; Danish–Belgian Research Group on Early Detection of Colorectal Cancer.
Abstract
FIT-based colorectal cancer screening has been implemented in many countries including Denmark, where 916 colorectal cancer and 4468 high- or medium-risk adenoma patients were identified within April-December 2014, among 16,806 subjects with a positive FIT test. Screening increases the overall requirements for colonoscopy, which may challenge the current capacity. Some countries have increased their initial FIT cut-off level in order to comply with lack of colonoscopy capacity. Many patients with neoplasia will not be detected, however, by using increased FIT cut-off levels. The number of patients with neoplastic lesions missed by increased cut-off levels appears to be much higher than expected. Therefore, tests that identify those patients missed by increased FIT cut-off levels must be developed. Preliminary results of determination of one of several biomarker entities currently under investigation show that nucleosome blood tests may be one option for identifying some of these patients. Implementation of a triage test consisting of FIT, blood-based biomarkers and plus/minus colonoscopy is suggested to identify subjects with FIT levels between the initial and the increased cut-off level that must be offered colonoscopy. In addition, triage may reduce the frequency of unnecessary colonoscopies by 25%.
[
b]My opinion:[/b]
fecal occult blood test (FOBT)+ neue Volition-Technologie (nucleosome test) reduzieren die Anzahl der nutzlosen Koloskopien um 25%. Es scheint negativ für Cosmo, aber es ist nicht so. In 75% der Kolonoskopien muss die suche nach Tumoren genauer sein, die Chancen, eine kleine zu finden, sind nur dank des Cosmo Lumeblue stark erhöht. Aslo gut! Keine Kolonosckopien mit alte methoden! Wenn die Volition-Technologie funktioniert, sollte Cosmo über die neuen Bluttests von Volition nachdenken und in ihre Produktpalette integrieren.

Fonti:
https://volitionrx.com//resources/downl ... bjects.pdf https://www.ncbi.nlm.nih.gov/pubmed/28271924

[blabla]

https://clinicaltrials.gov/ct2/show/NCT01847664

Phase II Studie Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis
Abgeschlossen: Juli 2017

Wo bleiben die Resultate?
Wann beginnt die Phase III Studie?
Habe diesbezüglich nirgends Informationen gefunden. Auch nicht in den letzten Präsentationen von Cosmo.

[kosh]